

LE GINECO A L'ASCO 2024 !

GYNECOLOGICAL CANCER RAPID ORAL SESSION (Samedi 1 juin à 8h – E451)

AXLerate-OC/ENGOT OV-66

Abstract #LBA5515

GYNECOLOGICAL CANCER ORAL SESSION (Dimanche 2 juin à 8h – Hall D2)

AGO-OVAR 2.29/ENGOT-ov34

Abstract #LBA5501

GYNECOLOGICAL CANCER ORAL POSTER (Lundi 3 juin de 9h à 12h – Hall A)

ENGOT-cx12 – Subsequent therapies

Abstract #5531

CHIVA - Kelim

Abstract #5560

INEOV – Survival outcomes and immune correlates

Abstract #5569

MIRASOL/ENGOT-ov55 -Elderly patients

Abstract #5580

ENDOLA – Molecular subtypes

Abstract #5605

REJOICE/ENGOT-ov77

Abstract #TPS5625

GYNECOLOGICAL CANCER RAPID ORAL SESSION

AXLerateOC /
ENGOT OV-66**Katherine Cynthia Fuh – Abstract LBA #5515**

AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer

GYNECOLOGICAL CANCER ORAL SESSION

AGO-OVAR 2.29 /
ENGOT-ov34**Frederik Marmé – Abstract #5501**

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

GYNECOLOGICAL CANCER ORAL POSTER SESSION

ENGOT-cx12 –
Subsequent therapies**Luis Manso – Abstract #5531**

Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301

CHIVA – Kelim

Benoît You – Abstract #5560

Consistent data about the predictive factors of the success of interval debulking surgery (CCO-IDS) in patients with advanced ovarian cancers in two large independent datasets

INEOV – Survival
outcomes and immune
correlates**Alexandra Leary – Abstract #5569**

Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates

MIRASOL/ENGOT-
ov55 -Elderly patients**Diana Bello – Abstract #5580**

Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator's choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FR α) expression

ENDOLA –
Molecular subtypes**Benoît You – Abstract #5605**

Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial

REJOICE /
ENGOT-ov77**Isabelle Ray-Coquard – Abstract#TPS5625**

REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum resistant ovarian cancer (OVC).